Lexaria Bioscience Corp.

LEXX·NasdaqCM·Healthcare
Compare
3.2700−0.0500 (−1.51%)today
At close: Oct 12, 4:00 PM EDT · May be delayed up to 15 min · USD

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close3.3200
Open3.1800
Day range3.18003.6235
52-week range2.770021.6000
Off day high−9.76%
Off 52-week high−84.86%
Volume65.92K
Avg. volume (3M)65.40K
Market cap6.89M
EPS (TTM)-5.10
Forward P/E-8.38
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.60
Shares outstanding2.11M
Short interest13.43% of float
Earnings dateJul 10, 2025 (est.)
Analyst target82.5000
Profit margin0.00%

Against its peers

Compare in full ›
LEXX MTVA LPCN BDRX NIKI JAGX
Market cap 6.89M 9.55M 13.69M 844.66K 9.42M 9.03M
P/E (TTM) — — — 0.0 — —
Forward P/E -8.4 — -1.3 — — -0.8
Price/book 1.1 1.4 0.6 0.0 0.1 3.4
Dividend yield — — — — — —
1-year change −75.49% −87.08% −48.29% −99.09% −81.01% −99.59%
Today −1.51% +2.84% −3.49% −16.73% −24.50% −3.13%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All LEXX news ›
Pharma in Focus·Positive

Expanded funding for four diabetes drugs

Pharma in Focus Connecting you with your industry every day Expanded funding for four diabetes drugs Up to 30,000 extra New Zealanders could have funded access to type 2 diabetes medications with Pharmac expanding the eligibility criteria…

MarketScreener·

Lexaria Bioscience Corp. : Insider Transactions

Follow insider transactions on Lexaria Bioscience Corp. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Lexaria Bioscience Corp. Latest insider transactions for Lexaria…

MarketScreener·Positive

Lexaria Bioscience Corp. Updates Progress on Human Study #7

Published on 05/05/2026 at 10:27 am EDT Lexaria Bioscience Corp. provided this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate 2 oral DehydraTECH-semaglutide (?DHT-sema?) compositions against Novo Nordisk?s commercially…

From articles in the 4Search news index.

In the news

17mentions in 30 days
11with it in the headline
Positivesentiment

Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Conservative index. Terms of use.